
ASX-listed small-cap drug companies are soaring as two firms announce plans to take advantage of Australia's medical regulator relaxing the rules around two mind-altering drugs.
The Therapeutic Goods Administration on Friday announced it was down-scheduling psilocybin and MDMA, allowing both to dispensed as of July 1 by authorised psychiatrists to treat certain mental health conditions.